Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Yacov Shacham

Tel-Aviv University, Israel

Title: New insights into Cardio-Renal interactions – Role of NGAL

Biography

Biography: Yacov Shacham

Abstract

Neutrophil gelatinase-associated lipocalin (NGAL) is an early marker of renal tubular damage. We investigated the incidence and possible implications of elevated NGAL levels (suggesting renal damage) compared to both functional and damage markers (manifested as serum creatinine (sCr) elevation) and no NGAL/sCr change, among ST elevation myocardial infarction patients (STEMI) treated with primary coronary intervention (PCI). We included 131 patients with STEMI treated with PCI. Blood samples for plasma NGAL were drawn 24 hours following PCI. We used the terms NGAL(−) or NGAL(+) with levels ≥100ng/ml suggesting renal tubular damage and the terms sCr(−) or sCr(+) to consensus diagnostic increases in sCr defining acute kidney injury. Patients were also assessed for in hospital-adverse outcomes.

Of the study patients (42%) were NGAL(-)/sCr(−), (44%)NGAL(+)/sCr(−), and 14% were both NGAL(+)/sCr(+). According to the three study groups there was a stepwise increase in the proportion of left ventricular ejection fraction ≤ 45% (43% vs. 60%. Vs. 72%; p=0.04), in–hospital adverse outcomes (9% vs, 14% vs. 56%; p<0.001) and their combination. Specifically, more NGAL(+)/sCr(−) patients developed the composite endpoint when compared to NGAL(-)/sCr(−) patients [64% vs.46%; OR 2.1 (95% CI 1.1–4.5), P=0.05]. A similar and consistent increase was observed in peak sCr, length of hospital stay and C-reactive protein levels.Similarly NGAL level aid in the early identification of acute kidney injury.In conclusion,elevated NGAL levels suggesting renal tubular damage, increased inflammation, or both, are common among STEMI patients and are associated with adverse outcomes even in the absence of diagnostic increase in sCr.